Literature DB >> 29653980

Controversial Issues in Thyroid Cancer Management.

R Michael Tuttle1.   

Abstract

The lack of prospective randomized clinical trials for most management topics in differentiated thyroid cancer forces us to make management recommendations based on retrospective observational data, which are often incomplete, subject to selection bias, and conflicting. Therefore, it is not surprising that many aspects of thyroid cancer management remain controversial and not well defined. This review will examine the controversies surrounding 3 important topics in thyroid cancer management: the option of thyroid lobectomy as initial therapy, the use of preoperative neck imaging to optimize the completeness of the initial surgery, and the selective use of radioactive iodine for remnant ablation, adjuvant treatment, or treatment for known persistent or recurrent disease. As thyroid cancer management moves toward a much more risk-adapted approach to personalized recommendations, clinicians and patients must balance the risks and benefits of the potential options to arrive at a plan that is optimized regarding both patient preferences/values and the philosophy/experience of the local disease management team.
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  radioactive iodine therapy; thyroid cancer; thyroid lobectomy

Mesh:

Substances:

Year:  2018        PMID: 29653980      PMCID: PMC6071505          DOI: 10.2967/jnumed.117.192559

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  33 in total

1.  Surgery for papillary thyroid carcinoma: is lobectomy enough?

Authors:  Abie H Mendelsohn; David A Elashoff; Elliot Abemayor; Maie A St John
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2010-11

Review 2.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

Review 3.  Selective use of RAI for ablation and adjuvant therapy after total thyroidectomy for differentiated thyroid cancer: a practical approach to clinical decision making.

Authors:  R Michael Tuttle; Mona M Sabra
Journal:  Oral Oncol       Date:  2013-04-16       Impact factor: 5.337

4.  Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.

Authors:  Hyeyeun Lim; Susan S Devesa; Julie A Sosa; David Check; Cari M Kitahara
Journal:  JAMA       Date:  2017-04-04       Impact factor: 56.272

5.  One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy.

Authors:  Rosália P Padovani; Teresa S Kasamatsu; Claudia C D Nakabashi; Cleber P Camacho; Danielle M Andreoni; Eduardo Z Malouf; Marilia M S Marone; Rui M B Maciel; Rosa Paula M Biscolla
Journal:  Thyroid       Date:  2012-07-24       Impact factor: 6.568

6.  Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer.

Authors:  John M Stulak; Clive S Grant; David R Farley; Geoffrey B Thompson; Jon A van Heerden; Ian D Hay; Carl C Reading; J William Charboneau
Journal:  Arch Surg       Date:  2006-05

7.  Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer.

Authors:  F Vaisman; A Shaha; S Fish; R Michael Tuttle
Journal:  Clin Endocrinol (Oxf)       Date:  2011-07       Impact factor: 3.478

8.  An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management.

Authors:  Eleonora Horvath; Sergio Majlis; Ricardo Rossi; Carmen Franco; Juan P Niedmann; Alex Castro; Miguel Dominguez
Journal:  J Clin Endocrinol Metab       Date:  2009-03-10       Impact factor: 5.958

9.  Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases.

Authors:  Kenichi Matsuzu; Kiminori Sugino; Katsuhiko Masudo; Mitsuji Nagahama; Wataru Kitagawa; Hiroshi Shibuya; Keiko Ohkuwa; Takashi Uruno; Akifumi Suzuki; Syunsuke Magoshi; Junko Akaishi; Chie Masaki; Michikazu Kawano; Nobuyasu Suganuma; Yasushi Rino; Munetaka Masuda; Kaori Kameyama; Hiroshi Takami; Koichi Ito
Journal:  World J Surg       Date:  2014-01       Impact factor: 3.352

Review 10.  Selected Controversies of Radioiodine Imaging and Therapy in Differentiated Thyroid Cancer.

Authors:  Douglas Van Nostrand
Journal:  Endocrinol Metab Clin North Am       Date:  2017-06-29       Impact factor: 4.741

View more
  17 in total

1.  Variations in radioiodine ablation: decision-making after total thyroidectomy.

Authors:  O Maas; F Forrer; M Maas; C M Panje; J Blautzik; M Brühlmeier; I Engel-Bicik; L Giovanella; A Haldemann; M E Kamel; S Kneifel; C Rottenburger; N Schaefer; M A Walter; S Weidner; P M Putora
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-09       Impact factor: 9.236

2.  [Current controversies in risk-adapted therapy in differentiated thyroid cancer: Is less (therapy) really more?]

Authors:  Amir Kurtaran; Brigitta Schmoll-Hauer; Christina Tugendsam
Journal:  Wien Med Wochenschr       Date:  2019-12-03

Review 3.  Total thyroidectomy versus thyroid lobectomy in the treatment of papillary carcinoma.

Authors:  Marco Raffaelli; Serena Elisa Tempera; Luca Sessa; Celestino Pio Lombardi; Carmela De Crea; Rocco Bellantone
Journal:  Gland Surg       Date:  2020-01

4.  Variations in Radioiodine Therapy in Europe: Decision-Making after Total Thyroidectomy.

Authors:  Flavio Forrer; Galina Farina Fischer; Ole Maas; Luca Giovanella; Martha Hoffmann; Ioannis Iakovou; Markus Luster; Jasna Mihailovic; Petra Petranovic Ovčariček; Alexis Vrachimis; Slimane Zerdoud; Paul Martin Putora
Journal:  Oncology       Date:  2021-11-17       Impact factor: 2.935

5.  Associations between essential microelements exposure and the aggressive clinicopathologic characteristics of papillary thyroid cancer.

Authors:  Ming-Jun Hu; Jia-Liu He; Xin-Ran Tong; Wan-Jun Yang; Huan-Huan Zhao; Guo-Ao Li; Fen Huang
Journal:  Biometals       Date:  2021-05-07       Impact factor: 2.949

6.  Modulating the extension of thyroidectomy in patients with papillary thyroid carcinoma pre-operatively eligible for lobectomy: reliability of ipsilateral central neck dissection.

Authors:  M Raffaelli; C De Crea; L Sessa; S E Tempera; G Fadda; A Pontecorvi; R Bellantone
Journal:  Endocrine       Date:  2020-08-20       Impact factor: 3.633

7.  Cost-effectiveness of computed tomography nodal scan in patients with papillary thyroid carcinoma.

Authors:  Zaid Al-Qurayshi; Gregory W Randolph; Emad Kandil
Journal:  Oral Oncol       Date:  2021-05-13       Impact factor: 5.972

8.  Immediate Surgery Might Be a Better Option for Subcapsular Thyroid Microcarcinomas.

Authors:  Jun Jiang; Hui Lu
Journal:  Int J Endocrinol       Date:  2019-04-03       Impact factor: 3.257

9.  miR‑27a‑3p regulates the inhibitory influence of endothelin 3 on the tumorigenesis of papillary thyroid cancer cells.

Authors:  Hongxin Chen; Binlin Cai; Kun Liu; Qingquan Hua
Journal:  Mol Med Rep       Date:  2021-02-04       Impact factor: 2.952

Review 10.  Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer.

Authors:  Dana M Hartl; Joanne Guerlain; Ingrid Breuskin; Julien Hadoux; Eric Baudin; Abir Al Ghuzlan; Marie Terroir-Cassou-Mounat; Livia Lamartina; Sophie Leboulleux
Journal:  Cancers (Basel)       Date:  2020-11-06       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.